Discovery could lead to new therapies for asthma, COPD

Jan 27, 2011

Researchers have proved that a single "master switch" enzyme, known as aldose reductase, is key in producing excess mucous that clogs the airways of people with asthma and chronic obstructive pulmonary disease (COPD). The enzyme's action can be blocked by drugs whose safety has been shown in clinical trials for other diseases – a discovery that could improve therapies for the 510 million people worldwide suffering from asthma and COPD.

The findings are from a University of Texas Medical Branch at Galveston study published in the online journal PLoS One.

Using cell culture and laboratory mouse experiments, the researchers showed that the enzyme, aldose reductase, is essential to a process known as goblet cell metaplasia that is seen in both asthma and COPD. In goblet cell metaplasia, exposure to allergens such as pollen, mold and dust mites initiates a series of biochemical reactions that causes the cells that line the air passages of the lungs to change from their normal state into so-called "goblet cells," which produce substantial amounts of excess mucus. Healthy individuals' lungs contain very few goblet cells, but patients who die from asthma — an estimated 5,000 people annually — have significantly higher numbers of these cells.

"Aldose reductase is key to a whole range of inflammation disorders, so it comes as no surprise that it should be crucial to the inflammatory processes that drive disease in asthma and COPD," said UTMB Health biochemistry and molecular biology professor Satish Srivastava, senior author of the paper. "The discovery that aldose reductase regulates mucus production and goblet cell metaplasia makes inhibition of this enzyme an attractive therapeutic option to reduce mucus-related airway obstructive diseases — and for the first time gives us a real chance to alter the course of the underlying disease in asthma and COPD."

According to Srivastava, aldose reductase inhibitors have a number of potential advantages over current therapies for asthma and COPD.

"Existing therapies for airway obstructive diseases provide relief by preventing allergic airway inflammation, but none of these drugs specifically address the problem of excessive mucus production; further, there is no convincing evidence that current therapies significantly reduce mortality associated with chronic asthma and COPD," Srivastava said. "Also, aldose reductase inhibitors can be given orally, unlike current inhaler-based treatments, so medication compliance could be better. And finally they can provide an alternative to steroid treatment for patients who either can't take steroids or find that steroids have no effect on their disease."

The next step, Srivastava said, is of the drugs as a therapy for asthma and COPD — a process that should be expedited since aldose reductase inhibitors have already undergone Phase III clinical trials for diabetic neuropathy. The UTMB Health Center for Technology Development views Srivastava's research as so promising that it has applied for patents to cover their use as potential treatments for , COPD and other inflammation-related disorders.

"Working closely with Professor Srivastava and other UTMB faculty, the next step is to prove the safety and efficacy of aldose reductase inhibitors for these conditions and develop them to improve the health of millions of people," said Jason Abair, associate vice president of the center. "We are looking forward to identifying appropriate partners in industry to help us reach this goal."

Explore further: Brittle bone disease: Drug research offers hope

Related Stories

Discovery may lead to powerful new therapy for asthma

Aug 11, 2009

University of Texas Medical Branch at Galveston researchers have found that a single enzyme is apparently critical to most allergen-provoked asthma attacks — and that activity of the enzyme, known as aldose reductase, can ...

HATS off to combat asthma

Dec 04, 2007

Two University of Nottingham studies exploring the causes and treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD) could lead to the development of drugs to battle these debilitating conditions.

Genetic variant may control lung function and risk of COPD

Dec 17, 2009

Researchers have discovered evidence that suggests a genetic variant may be associated with better preserved lung function among children with asthma and adults who smoke, according to a new study funded by the National Heart, ...

Personalized therapy for asthma and COPD could soon be here

May 18, 2008

Researchers at Washington University School of Medicine in St. Louis have defined a new type of immune response that is activated in patients with severe asthma and COPD (chronic obstructive pulmonary disease). Their discovery ...

Recommended for you

Brittle bone disease: Drug research offers hope

45 minutes ago

New research at the University of Michigan offers evidence that a drug being developed to treat osteoporosis may also be useful for treating osteogenesis imperfecta or brittle bone disease, a rare but potentially debilitating ...

Why gastrointestinal disorders afflict women more often

5 hours ago

Women are more likely to have irritable bowel syndrome and other gastrointestinal (GI) disorders than men are. Although this could be because men and women handle the condition differently— "toughing it out" versus getting ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.